GlassScriptPhysician profile
Maggie A Winter
NPI 1053691899
$1,726.83
in general payments reported to CMS, 2019-2025
27 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.54 · 2022: $242 · 2023: $457 · 2024: $491 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.37 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $199.16 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $164.23 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $116.76 | 2022-2024 | Veozah |
| Novo Nordisk INC | $100.82 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $97.88 | 2022-2025 | |
| Esperion Therapeutics, INC. | $70.41 | 2025 | Nexletol |
| Pfizer INC. | $65.86 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $64.78 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $64.29 | 2022-2024 | |
| Glaxosmithkline, LLC. | $60.41 | 2022-2025 | Trelegy Ellipta |
| Bausch Health US, LLC | $51.29 | 2022-2023 | Wellbutrin, Aplenzin |
| Alk-Abello, INC | $45.83 | 2024 | Odactra, Grastek, Ragwitek |
| Exact Sciences Corporation | $45.08 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $40.36 | 2022-2023 | Freestyle Libre 2 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.44 | 2021-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $32.56 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $27.87 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Corcept Therapeutics | $20.58 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $18.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.70 | 2024 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $17.45 | 2025 | Neffy |
| Phathom Pharmaceuticals, INC. | $16.97 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $16.09 | 2025 | Zoryve |
| Almatica Pharma LLC | $15.95 | 2025 | Teriparatide, Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.